Pharma Two B
  • Home
  • Our Company
    • Who We Are
    • Pharma Two B Team
    • Board of Directors
  • Our Focus
    • Our Development Approach
    • Our Regulatory Approach
    • Intellectual Property
    • Strategic Partnerships
  • Patients & Families
    • Parkinson’s disease
    • Resources
  • Our Pipeline
    • P2B001
    • Clinical Trials
    • Pipeline and Future Products
    • Possible Risk Related to P2B001 Clinical Trials
    • Drug-drug combinations
  • News & Events
    • Press Releases
    • Events
    • Publications
  • Contact Us
  • Home
  • Our Company
    • Who We Are
    • Pharma Two B Team
    • Board of Directors
  • Our Focus
    • Our Development Approach
    • Our Regulatory Approach
    • Intellectual Property
    • Strategic Partnerships
  • Patients & Families
    • Parkinson’s disease
    • Resources
  • Our Pipeline
    • P2B001
    • Clinical Trials
    • Pipeline and Future Products
    • Possible Risk Related to P2B001 Clinical Trials
    • Drug-drug combinations
  • News & Events
    • Press Releases
    • Events
    • Publications
  • Contact Us
Pharma Two B
  • Home
  • Our Company
    • Who We Are
    • Pharma Two B Team
    • Board of Directors
  • Our Focus
    • Our Development Approach
    • Our Regulatory Approach
    • Intellectual Property
    • Strategic Partnerships
  • Patients & Families
    • Parkinson’s disease
    • Resources
  • Our Pipeline
    • P2B001
    • Clinical Trials
    • Pipeline and Future Products
    • Possible Risk Related to P2B001 Clinical Trials
    • Drug-drug combinations
  • News & Events
    • Press Releases
    • Events
    • Publications
  • Contact Us
  • Home
  • Our Company
    • Who We Are
    • Pharma Two B Team
    • Board of Directors
  • Our Focus
    • Our Development Approach
    • Our Regulatory Approach
    • Intellectual Property
    • Strategic Partnerships
  • Patients & Families
    • Parkinson’s disease
    • Resources
  • Our Pipeline
    • P2B001
    • Clinical Trials
    • Pipeline and Future Products
    • Possible Risk Related to P2B001 Clinical Trials
    • Drug-drug combinations
  • News & Events
    • Press Releases
    • Events
    • Publications
  • Contact Us
 
We at Pharma Two B are striving to make your life better by developing innovative products based on previously approved drugs.
Learn more
“Sometimes I can’t drink in a meeting because I’m afraid to spill my coffee”
We at Pharma Two B are striving to make your life better by developing innovative products based on previously approved drugs.
Learn more
“There are mornings that my wife has to tie my shoes”
We at Pharma Two B are striving to make your life better by developing innovative products based on previously approved drugs.
Learn more
“It happened that people can’t understand my speech”
We at Pharma Two B are striving to make your life better by developing innovative products based on previously approved drugs.
Learn more
“My grandchild comes over and I fall asleep while we’re playing”
We at Pharma Two B are striving to make your life better by developing innovative products based on previously approved drugs.
Learn more
Previous
Next

Our Mission

Developing innovative  products based on    previously approved drugs, by maximizing the potential of their mechanism of action, adapting doses, delivery modes, and utilizing synergistic effects in combination products.

Pharma Two B
Pharma Two B Ltd. 3 Pekeris Street, Weizmann Science Park, Rehovot, 7670203 Israel
Tel: +972-8-9472672 , Fax: +972-8-9366832
Privacy Policy    Terms of Use    PharmaTwoB. All rights reserved © 2017
Scroll to top